TX-SAFEGUARD-GLOBAL
27.1.2022 13:09:03 CET | Business Wire | Press release
Safeguard Global, a global future of work company, announced today its acquisition of Global Upside, a global expansion technology and services company based in San Jose, Calif. The deal expands the company’s ability to help emerging and established multinationals compliantly recruit, hire, pay—and now set up operations—anywhere in the world. The move also helps Safeguard Global continue building out its workforce management technology platform, Global Unity, to be able to provide end-to-end digital service.
The acquisition, part of an aggressive growth strategy, combines the momentum of the two hyper-growth companies in an industry that is growing quickly to meet increasing demand for workforce management solutions. It makes Safeguard Global, which founded the Employer of Record (EOR) industry in 2011, the largest EOR in global coverage and breadth of services. It also adds new markets in Latin America, Eastern Europe, Africa and Asia.
“The team at Global Upside built an amazing company with complementary solutions to ours,” says Bjorn Reynolds, Chief Executive Officer and founder of Safeguard Global. “Adding entity setup to our portfolio bridges a critical gap that allows us to partner with clients seamlessly as their business needs evolve. This makes us unique because we are the only company to offer clients the technology and resources to grow compliantly with one single partner. We help them hire workers of any classification in new markets, set up their own in-country entities to directly hire when the time is right, and centralize global payroll when operating in multiple markets around the world.”
Safeguard Global helps companies compete in a rapidly changing landscape. With market-leading employment and payroll solutions, Safeguard Global equips organizations with the technology, local market expertise and service to create opportunities that attract and retain the best talent and fuel their business growth.
“The future of work is about creating Work in Any Way experiences, which diversify not just where but how and when companies grow and people work,” Reynolds continues. “Safeguard Global’s solutions and technology enable flexibility in how companies expand their businesses and the types of work experiences they provide. That's a competitive advantage. Acquiring Global Upside provides us with more scale, support and capability to lead our clients and our industry through the future of work.”
About Safeguard Global
Safeguard Global is a future of work company that builds adaptive workforce management solutions for organizations seeking to thrive in the global economy. Safeguard Global enables success through smarter, more efficient global employee management, recruitment, payroll, onboarding, expense management and more, all powered by industry-leading data, technology, services and local market expertise. To learn more, visit www.safeguardglobal.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220126005640/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership4.8.2026 11:00:00 CEST | Press release
The integration gives eligible WHOOP members seamless access to the only FDA-cleared hormone-free birth control app, with the first year of Natural Cycles° included for those new to the app as part of their WHOOP membership. WHOOP, the human performance company, today announced an expansion of its women’s health offering through an integration with Natural Cycles° (NC°), the only FDA-cleared, hormone-free birth control app. WHOOP is offering a 12-month subscription to the NC° app to eligible new Natural Cycles users. Members with compatible WHOOP devices can now automatically share overnight skin temperature with the NC° app to enable personalized fertility insights and hormone-free birth control. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260804399367/en/ WHOOP Expands Commitment to Women's Health by Including One-Year Subscription of Natural Cycles° App in Membership The Natural Cycles app, a Class II medical device, u
Alphatax Makes Two Acquisitions to Strengthen Transfer Pricing Capabilities4.8.2026 10:00:00 CEST | Press release
Acquisitions Expand Transfer Pricing Offering and Support Long-Term Platform Strategy Alphatax, the global tax compliance software provider, has today announced the acquisitions of TP Accurate and Intra Pricing Solutions, expanding its transfer pricing capabilities and reinforcing its ambition to build the world's first tax operating system. The acquisitions strengthen Alphatax's transfer pricing portfolio with complementary capabilities across financial transactions and documentation. TP Accurate provides specialist software for intra-group financing arrangements, while Intra Pricing Solutions' flagship product, TPGenie, enables multinational organisations and advisors to produce transfer pricing documentation using intelligent automation and AI. Together, they expand Alphatax's ability to support the full transfer pricing lifecycle, helping customers manage compliance more efficiently while improving governance and reducing audit risk. They also represent another step towards Alphata
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom